Compare AMSC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSC | ODTX |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2012 | 2025 |
| Metric | AMSC | ODTX |
|---|---|---|
| Price | $23.01 | $19.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $61.75 | $35.33 |
| AVG Volume (30 Days) | ★ 743.4K | 254.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1806.25 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $900,000.00 | N/A |
| Revenue This Year | $22.95 | N/A |
| Revenue Next Year | $15.15 | N/A |
| P/E Ratio | $97.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.08 | $15.10 |
| 52 Week High | $60.18 | $29.05 |
| Indicator | AMSC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.13 | 47.47 |
| Support Level | N/A | $15.73 |
| Resistance Level | $32.24 | $19.60 |
| Average True Range (ATR) | 1.77 | 1.75 |
| MACD | -0.21 | 0.18 |
| Stochastic Oscillator | 13.33 | 42.36 |
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.